InvestSMART

Acrux Limited (ASX: ACR) - Announcements

Current share price for ACR : $0.009 0.001 (10%)+

ASX company news and announcements for Acrux Limited (ACR) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Acrux Limited (ACR) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Acrux Limited (ACR), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Acrux Limited (ACR)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$5 Acrux signs Ellavie distribution agreement for South Korea 10 Jul 2009 12:24PM $1.140 $0.009 fallen by 99.21%
$5 Acrux signs Ellavie distribution agreement for Switzerland 19 Jun 2009 6:22PM $1.240 $0.009 fallen by 99.27%
$5 Arbitration Panel Rules in Favour of Acrux 19 Jun 2009 10:19AM $1.240 $0.009 fallen by 99.27%
$5 Acrux signs Ellavie Distribution Agreement for South Africa 4 Jun 2009 10:52AM $1.325 $0.009 fallen by 99.32%
$5 Response to an ASX Price Query 2 Jun 2009 10:08AM $1.300 $0.009 fallen by 99.31%
$5 Response to an ASX Price Query 12 May 2009 9:29AM $0.875 $0.009 fallen by 98.97%
$5 Appendix 4C - Quarterly Cash Flow 23 Apr 2009 12:54PM $0.650 $0.009 fallen by 98.62%
$5 Acrux receives interim arbitration ruling 14 Apr 2009 9:47AM $0.630 $0.009 fallen by 98.57%
$5 Acrux completes enrolment in Phase 3 trial of AXIRON 9 Mar 2009 9:42AM $0.435 $0.009 fallen by 97.93%
$5 Update on Evamist and KV Pharmaceutical 3 Mar 2009 9:59AM $0.450 $0.009 fallen by 98%
$5 Half Year Accounts and Appendix 4D 25 Feb 2009 10:17AM $0.440 $0.009 fallen by 97.95%
$5 Positive clinical trial results for contraceptive spray 20 Feb 2009 7:25PM $0.450 $0.009 fallen by 98%
$5 Appendix 4C quarterly cash flow report 30 Jan 2009 4:58PM $0.450 $0.009 fallen by 98%
$5 Acrux ceases investment in Fentanyl MDTS 30 Jan 2009 4:11PM $0.460 $0.009 fallen by 98.04%
$5 Response to an ASX Price Query 12 Jan 2009 9:57AM $0.600 $0.009 fallen by 98.50%
$5 SUBMISSION TO FDA OF FIRST ANIMAL HEALTH PRODUCT 15 Dec 2008 11:47AM $0.485 $0.009 fallen by 98.14%
$5 Enrolment 50% completed in testosterone lotion Phase 3 trial 20 Nov 2008 10:41AM $0.420 $0.009 fallen by 97.86%
$5 Acrux core patent approved in Japan 19 Nov 2008 9:43AM $0.560 $0.009 fallen by 98.39%
$5 Acrux adds topical pain relief drugs to product pipeline 12 Nov 2008 10:16AM $0.600 $0.009 fallen by 98.50%
$5 Appendix 4C Quarterly cash flow report 29 Oct 2008 6:31PM $0.680 $0.009 fallen by 98.68%
$5 Appendix 4E and 30 June 2008 Financial Report 28 Aug 2008 2:55PM $1.150 $0.009 fallen by 99.22%
$5 Organon project halted - Acrux continues contraceptive spray 15 Aug 2008 12:26PM $1.200 $0.009 fallen by 99.25%
$5 Commercial manufacturing alliance with Orion Corporation 14 Aug 2008 8:22AM $1.275 $0.009 fallen by 99.29%
$5 New agreement with KV for Evamist and six further products 12 Aug 2008 8:59AM $1.210 $0.009 fallen by 99.26%
$5 Trading Halt 11 Aug 2008 10:28AM n/a $0.009 n/a

601 - 625 of 696 results

Page 25 of 28

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.